Back from the brink: EGFR inhibition in gastroesophageal cancer

Mark R. Openshaw; David J. Pinato; Nicola Valeri

doi:10.1158/1078-0432.CCR-21-0533

Back from the brink: EGFR inhibition in gastroesophageal cancer

Mark R. Openshaw
, David J. Pinato
, Nicola Valeri

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.

Original language	English
Pages (from-to)	2964-2966
Number of pages	3
Journal	Clinical Cancer Research
Volume	27
Issue number	11
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-0533
Publication status	Published - 1 Jun 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1158/1078-0432.CCR-21-0533

Cite this

@article{f1d0fb7690f54929a77578d64d687a51,

title = "Back from the brink: EGFR inhibition in gastroesophageal cancer",

abstract = "Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.",

author = "Openshaw, \{Mark R.\} and Pinato, \{David J.\} and Nicola Valeri",

note = "Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",

year = "2021",

month = jun,

day = "1",

doi = "10.1158/1078-0432.CCR-21-0533",

language = "English",

volume = "27",

pages = "2964--2966",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "11",

}

TY - JOUR

T1 - Back from the brink

T2 - EGFR inhibition in gastroesophageal cancer

AU - Openshaw, Mark R.

AU - Pinato, David J.

AU - Valeri, Nicola

PY - 2021/6/1

Y1 - 2021/6/1

N2 - Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.

AB - Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.

UR - https://www.scopus.com/pages/publications/85106970456

U2 - 10.1158/1078-0432.CCR-21-0533

DO - 10.1158/1078-0432.CCR-21-0533

M3 - Article

SN - 1078-0432

VL - 27

SP - 2964

EP - 2966

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 11

ER -

Back from the brink: EGFR inhibition in gastroesophageal cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this